Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1 +) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1 Meeting Abstract
| Authors: | Lin, J. J.; Drilon, A. E.; Cho, B. C.; Felip, E.; De Langen, A.; Yang, N.; Kim, S. W.; Lu, S.; Kao, S. C. H.; Velcheti, V.; Moro Sibilot, D. L.; Solomon, B. J.; Dziadziuszko, R.; Krebs, M. G.; Cheema, P. K.; Dooms, C. A.; Stopatschinskaja, S.; Trone, D.; Ades, F.; Camidge, D. R. |
| Abstract Title: | Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1 +) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1 |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.9017 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 9017 -- Meeting also presented virtually -- Source: Cinahl |
